---
title: "Sensus Healthcare: A Tough Q1 2025 Awaits Ahead"
date: "2025-02-07 17:04:47"
summary: "kali9  Investment thesis Sensus Healthcare (NASDAQ:SRTS) is a company that develops equipment to treat skin problems, including non-melanoma cancer. The company recently presented full year 2024 results in which it appears that Q1 2025 will have considerably"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/514880133/image_514880133.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Dermatologist examining patient for signs of skin cancer](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/514880133/image_514880133.jpg?io=getty-c-w750) 



kali9





Investment thesis
-----------------

Sensus Healthcare (NASDAQ:[SRTS](https://seekingalpha.com/symbol/SRTS#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link)) is a company that develops equipment to treat skin problems, including non-melanoma cancer. The company recently presented [full year 2024 results](https://sensushealthcare.com/sensus-healthcare-reports-fourth-quarter-and-full-year-2024-financial-results/) in which it appears that Q1 2025 will have considerably

[seekalpha_articles](https://seekingalpha.com/article/4756046-sensus-healthcare-a-tough-q1-2025-awaits-ahead)
